Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tempest Therapeutics, Inc.TPST · Entity 7734 | Corporate Controller | June 21, 2022 | June 22, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tempest Therapeutics, Inc.
Report date June 21, 2022 · Filed June 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.35 · Expires 2032-06-20 | Direct | 8,477 |
Reported balance
After 2022-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-21 · Grant · Acquired 8,477 · Balance 8,477 F1: Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2022 Filed Jun 22, 2022 16:38 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 8,477 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001179110-22-003402 · edgar.xml · derivative · entry 1 Lorenzo Pierre · CIK 0001869915 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,477 Underlying: Common Stock · 8,477 shares Expires 2032-06-20 F1 · derivative.exercise_date: Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 19:26 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001209191-22-002253 · doc4.xml · derivative · entry 1 Lorenzo Pierre · CIK 0001869915 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2032-01-03 F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 4, 2022, subject to the reporting person's continued service. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:53 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 48,535 | Not disclosed Strike: $26.40 | Not disclosed |
DisclosureSEC source: 0001140361-21-022781 · form4.xml · derivative · entry 4 Lorenzo Pierre · CIK 0001869915 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,535 Underlying: Common Stock · 48,535 shares Expires 2031-04-28 F1 · price: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc." F4 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of Closing, June 25, 2021, subject to the reporting person's continued service. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:53 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 1,234 | Not disclosed Strike: $10.25 | Not disclosed |
DisclosureSEC source: 0001140361-21-022781 · form4.xml · derivative · entry 3 Lorenzo Pierre · CIK 0001869915 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,234 Underlying: Common Stock · 1,234 shares Expires 2031-03-09 F1 · price: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc." F3 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of March 5, 2021, subject to the reporting person's continued service. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:53 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 4,830 | Not disclosed Strike: $5.90 | Not disclosed |
DisclosureSEC source: 0001140361-21-022781 · form4.xml · derivative · entry 2 Lorenzo Pierre · CIK 0001869915 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,830 Underlying: Common Stock · 4,830 shares Expires 2030-11-15 F1 · price: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc." F2 · derivative.exercise_date: One-fourth of the shares underlying this option vest on November 16, 2021, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:53 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantCommon Stock | 53 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-022781 · form4.xml · nonDerivative · entry 1 Lorenzo Pierre · CIK 0001869915 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53 F1 · price: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc." Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.